Skip to content
Study details
Enrolling now

AWARE: Managing ADHD in Autism Spectrum Disorder

Daniel Coury
NCT IDNCT05916339ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

500

Study length

about 4.2 years

Ages

4–17

Locations

10 sites in CA, MA, ME +4

What this study is about

This trial is testing two different types of stimulant medication and an alpha-2 agonist to see which works best for children with both ADHD and autism. The goal is to help doctors choose the right treatment more effectively, reducing the need for repeated trials of multiple medications.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant
  • 2.Take Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

NERVOUS SYSTEM, stimulant (CNS stimulant; blocks reuptake of dopamine and norepinephrine)

Drug routes

oral (Disintegrating Oral Tablet)

Body systems

Psychiatry / Mental Health